Enanta Pharmaceuticals Inc (ENTA)

[floblu14]

This might be far-fetched or I might be fantasizing - but, ENTA might go after accelerated approval since they now have additional funds & most important - the 2 drugs have shown successful outcomes for a serious & deadly disease -

AI -
A drug company can get accelerated approval after clinical trial 2 by showing that the drug treats a serious condition, has a meaningful advantage over existing therapies, and demonstrates a surrogate endpoint that is reasonably likely to predict clinical benefit. The company must also engage with the FDA early in development and demonstrate that it can conduct a timely confirmatory trial to verify the drug's benefit after approval.

Several drugs have received accelerated approval based on Phase 2 clinical trials, including Odronextamab for lymphoma, Elevidys for Duchenne muscular dystrophy, and Tecartus for mantle cell lymphoma. The process allows for earlier approval of drugs that treat serious conditions and may be based on a "surrogate endpoint" that is reasonably likely to predict a clinical benefit, although further trials are typically required.

Furthermore -
Examples of drugs granted accelerated approval based on Phase 2 trials:
Odronextamab: This bispecific antibody was submitted for accelerated approval for follicular lymphoma and diffuse large B-cell lymphoma, supported by Phase 1 and Phase 2 trial data.
Elevidys: This gene therapy received accelerated approval for Duchenne muscular dystrophy based on data showing it increased a certain protein, a surrogate endpoint reasonably likely to predict clinical benefit.
Tecartus: A cell therapy for mantle cell lymphoma, it was granted accelerated approval.
Gleevec: This drug for chronic myeloid leukemia (CML) received accelerated approval after submitting results from three large Phase 2 trials.
Clofarabine: An oral treatment for pediatric acute lymphoblastic leukemia (ALL), it was approved based on the results of two trials.
Nelarabine: Another T-cell ALL and lymphoma drug, it was approved based on two trials.
Ocaliva: This drug for primary biliary cholangitis (PBC) received its initial accelerated approval based on Phase 2 results.
Tofersen: This drug for SOD1-ALS treatment was granted accelerated approval.
Keytruda: A blockbuster cancer treatment, it has received multiple accelerated approvals based on different trials, including Phase 2 trials.

Comments?